Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505983 | 0.79 | LMNA (0.43) | LMNACYP3A4PMP22MAPTAPEX1 | |
| SCHEMBL1037540 | 0.79 | CYP2A6 (0.44) | LMNACYP3A4PMP22MAPTAPEX1 | |
| SCHEMBL31710929 | 0.75 | LMNA (0.40) | LMNACYP3A4PMP22MAPTAPEX1 | |
| SCHEMBL22589531 | 0.75 | CYP1A2 (0.41) | LMNACYP3A4PMP22MAPTAPEX1 | |
| SCHEMBL19496922 | 0.75 | LMNA (0.40) | LMNACYP3A4PMP22MAPTAPEX1 | |
| SCHEMBL4187576 | 0.75 | NT5E (0.42) | LMNACYP3A4PMP22MAPTAPEX1 | |
| SCHEMBL2312719 | 0.75 | ADORA2A (0.46) | LMNAPMP22MAPTKDM4ECYP2C19 | |
| SCHEMBL9985459 | 0.75 | LMNA (0.40) | LMNACYP3A4PMP22MAPTAPEX1 | |
| SCHEMBL523735 | 0.71 | MAPT (0.58) | LMNACYP3A4PMP22MAPTAPEX1 | |
| SCHEMBL18529914 | 0.71 | KDM4E (0.35) | LMNACYP3A4PMP22PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054466-A1 | TUMOR BIOMARKERS AND USE THEREOF | CUREGENIX CORPORATION | 2021-02-25 | — | — | US | disclosed |
| US-20210054466-A1 | TUMOR BIOMARKERS AND USE THEREOF | CUREGENIX CORPORATION | 2021-02-25 | — | — | US | disclosed |
| US-10660889-B2 | Compounds for treatment of cancer | CUREGENIX, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-10660889-B2 | Compounds for treatment of cancer | CUREGENIX, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20190209558-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190209558-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190142827-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CUREGENIX, INC. (CN) | 2019-05-16 | — | — | US | disclosed |
| US-20190142827-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CUREGENIX, INC. (CN) | 2019-05-16 | — | — | US | disclosed |
| US-10285988-B2 | Compounds for treatment of fibrosis diseases | CUREGENIX, INC. (CN) | 2019-05-14 | — | — | US | disclosed |
| US-10285988-B2 | Compounds for treatment of fibrosis diseases | CUREGENIX, INC. (CN) | 2019-05-14 | — | — | US | disclosed |
| WO-2014165232-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CUREGENIX, INC. (CN) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165232-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CUREGENIX, INC. (CN) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014159733-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159733-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013185353-A1 | COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF | CUREGENIX INC. (CN) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013185353-A1 | COMPOUND AS WNT SIGNALING INHIBITOR, COMPOSITION, AND USE THEREOF | CUREGENIX INC. (CN) | 2013-12-19 | — | — | WO | disclosed |
| US-8093243-B2 | Inhibit the function of the non-structural proteins (NS5A) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093243-B2 | Inhibit the function of the non-structural proteins (NS5A) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10285988-B2 | Compounds for treatment of fibrosis diseases | WNT1, SFRP1, WNT3 | LMNA 2744/4885CYP3A4 4412/4885PMP22 3951/4885 |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | LMNA 3159/4885CYP3A4 1107/4885PMP22 4074/4885 |
| US-20190209558-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | WNT1, SFRP1, WNT3 | LMNA 2744/4885CYP3A4 4412/4885PMP22 3951/4885 |
| US-10660889-B2 | Compounds for treatment of cancer | WNT1, CTNNB1, WNT3 | LMNA 3824/4885CYP3A4 3541/4885PMP22 4881/4885 |
| US-20190142827-A1 | COMPOUNDS FOR TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | LMNA 3824/4885CYP3A4 3541/4885PMP22 4881/4885 |
| US-20210054466-A1 | TUMOR BIOMARKERS AND USE THEREOF | CTNNB1, CTNNBL1, WNT1 | LMNA 2872/4885CYP3A4 4823/4885PMP22 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.